Abstract:
The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in one procedure, that can easily be accomplished by a dental professional or a medical assistant. Chronic periodontitis and/or caries, the result of an imbalance of the microbial composition of the biofilm on the teeth, at the gum line or under the gum line, can be treated by the application of PREVORA, following standard oral cleaning and debriding of plaque at or below the gum line, to restore the balance of the biofilm to more normal, symbiotic composition. This treatment method is particularly useful in conjunction with the medical management of chronic diseases, such as type 2 diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and the like, which have been associated with periodontopathogens. As an example, the topical dental solution is applied to the teeth of an adult diabetic patient every 3 months for the first year, fol lowed by semi-annual single applications for as long as the patient remains at risk for either periodontal disease or caries.
Abstract:
The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in one procedure, that can easily be accomplished by a dental professional or a medical assistant. Chronic periodontitis and/or caries, the result of an imbalance of the microbial composition of the biofilm on the teeth, at the gum line or under the gum line, can be treated by the application of PREVORA, following standard oral cleaning and debriding of plaque at or below the gum line, to restore the balance of the biofilm to more normal, symbiotic composition. This treatment method is particularly useful in conjunction with the medical management of chronic diseases, such as type 2 diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and the like, which have been associated with periodontopathogens. As an example, the topical dental solution is applied to the teeth of an adult diabetic patient every 3 months for the first year, fol lowed by semi-annual single applications for as long as the patient remains at risk for either periodontal disease or caries.
Abstract:
A method of manufacturing a topical, antibacterial coating containing chlorhexidine, as the active anti-bacterial agent, in a matrix of the natural substance, specifically a compendial grade of Sumatra benzoin, so as to comply with existing specifications for the drug product under international regulatory standards by novel HPLC and colorimetric test methods.
Abstract:
A method of manufacturing a topical, antibacterial coating containing chlorhexidine, as the active anti-bacterial agent, in a matrix of the natural substance, specifically a compendial grade of Sumatra benzoin, so as to comply with existing specifications for the drug product under international regulatory standards by novel HPLC and colorimetric test methods.
Abstract:
Topical application of a pharmacologically-inactive, inert polymeric solution to teeth affords a temporary, protective barrier for pharmacologically-active compounds that have been previously applied topically to the tooth surfaces for caries reduction. In a method of use, an aqueous dispersion polymethylmethacrylate (PMMA) and a suitable plasticizer are applied topically to the tooth surface immediately after the topical application of chlorhexidine or fluoride. The inert coating thus formed is distinct from any pharmacologically-active substance, and remains on the tooth surface until abraded by the chewing of hard foods. In a composition of matter, the solution contains ammonio methacrylate copolymer, type B USP/NF of between 20% and 35% w/w; triethyl citrate USP/NF of between 1% and 10% w/w; and purified water of between 60% and 70% w/w. The ammonio methacrylate copolymer is preferably EUDRAGIT RS 30 D brand available form Rohm GmbH.
Abstract:
Topical application of a solution of the antimicrobial chlorhexidine to teeth, particularly including exposed root surfaces, prevents the destruction of exposed cementum and associated exposed enamel at the cementum-enamel junction on tooth root surfaces (root caries) and the inflammation of the gingival tissue. In a method of use, a topical solution containing 10% (w/v) chlorhexidine, 20% (w/v) Sumatra benzoin, and 70% (w/v) ethanol is applied to the appropriate area of the tooth surface, followed immediately by application of a sealant which is a solution containing 29% (w/v) medical-grade polyurethane in 49% (w/v) acetone and 22% (w/v) ethyl acetate. Application of the chlorhexidine and sealant to the tooth cementum and gingival margin of "at risk" older adult patients has significantly reduced the prevalence and incidence of root caries and gingival inflammation.